Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
 Securities Case - EconoTimes)
NEW YORK, Dec. 08, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA). The class action is on behalf of a class consisting of all persons who purchased Teva American Depositary Shares (“ADSs”) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). Teva investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3027-teva-pharmaceutical-industries-limited-teva.html.
Teva primarily develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines. Teva ADSs are traded on the New York Stock Exchange (“NYSE”) under the ticker symbol “TEVA.”
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Teva for alleged price manipulation; (3) as a result, Teva lacked effective internal controls; and (4) consequently, Teva's public statements were materially false and misleading at all relevant times.
What You Can Do
If you purchased Teva ADSs, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
